394 related articles for article (PubMed ID: 29055700)
21. Study the anticancer efficacy of doxorubicin-loaded redox-responsive chitosan-derived nanoparticles in the MDA-MB-231 cell line.
Antoniraj MG; Dhayanandamoorthy Y; Ponnuchamy K; Kandasamy R; Pandima Devi K
Carbohydr Res; 2024 Feb; 536():109049. PubMed ID: 38346357
[TBL] [Abstract][Full Text] [Related]
22. Milk derived colloid as a novel drug delivery carrier for breast cancer.
Hayashi M; Silanikove N; Chang X; Ravi R; Pham V; Baia G; Paz K; Brait M; Koch WM; Sidransky D
Cancer Biol Ther; 2015; 16(8):1184-93. PubMed ID: 26046946
[TBL] [Abstract][Full Text] [Related]
23. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin Intracellular Release
El Founi M; Laroui H; Canup BSB; Ametepe JS; Vanderesse R; Acherar S; Babin J; Ferji K; Chevalot I; Six JL
ACS Appl Bio Mater; 2021 Mar; 4(3):2742-2751. PubMed ID: 35014313
[TBL] [Abstract][Full Text] [Related]
25. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
26. ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy.
Zhou J; Li K; Zang X; Xie Y; Song J; Chen X
Int J Nanomedicine; 2023; 18():1381-1397. PubMed ID: 36987427
[TBL] [Abstract][Full Text] [Related]
27. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
28. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
29. Preparation of pH-Sensitive Dextran Nanoparticle for Doxorubicin Delivery.
Wang B; Liu P; Shi B; Gao J; Gong P
J Nanosci Nanotechnol; 2015 Apr; 15(4):2613-8. PubMed ID: 26353472
[TBL] [Abstract][Full Text] [Related]
30. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
31. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
[TBL] [Abstract][Full Text] [Related]
32. Optical Properties of Doxorubicin Hydrochloride Load and Release on Silica Nanoparticle Platform.
Nguyen TN; Nguyen TT; Nghiem THL; Nguyen DT; Tran TTH; Vu D; Nguyen TBN; Nguyen TMH; Nguyen VT; Nguyen MH
Molecules; 2021 Jun; 26(13):. PubMed ID: 34209621
[TBL] [Abstract][Full Text] [Related]
33. Simply constructed chitosan nanocarriers with precise spatiotemporal control for efficient intracellular drug delivery.
Kong M; Zuo Y; Wang M; Bai X; Feng C; Chen X
Carbohydr Polym; 2017 Aug; 169():341-350. PubMed ID: 28504154
[TBL] [Abstract][Full Text] [Related]
34. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
35. Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin.
Sivasubramanian M; Thambi T; Deepagan VG; Saravanakumar G; Ko H; Kang YM; Park JH
J Nanosci Nanotechnol; 2013 Nov; 13(11):7271-8. PubMed ID: 24245242
[TBL] [Abstract][Full Text] [Related]
36. Dual stimuli polysaccharide nanovesicles for conjugated and physically loaded doxorubicin delivery in breast cancer cells.
Pramod PS; Shah R; Jayakannan M
Nanoscale; 2015 Apr; 7(15):6636-52. PubMed ID: 25797322
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin-loaded biodegradable self-assembly zein nanoparticle and its anti-cancer effect: Preparation, in vitro evaluation, and cellular uptake.
Dong F; Dong X; Zhou L; Xiao H; Ho PY; Wong MS; Wang Y
Colloids Surf B Biointerfaces; 2016 Apr; 140():324-331. PubMed ID: 26764113
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
39. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
